[{"address1": "11455 El Camino Real", "address2": "Suite 250", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 369 7100", "website": "https://www.meipharma.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.", "fullTimeEmployees": 46, "companyOfficers": [{"maxAge": 1, "name": "Mr. Justin J. File", "age": 53, "title": "Acting CEO, CFO & Corporate Secretary", "yearBorn": 1970, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Yomara  Gomez-Naiden", "title": "Senior Vice President of Operations & Quality", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Nicole Chyoko Iida", "title": "Vice President of Legal Affairs", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Anne  Frese", "title": "Chief People Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert D. Mass", "age": 69, "title": "Strategic Advisor", "yearBorn": 1954, "fiscalYear": 2021, "totalPay": 201676, "exercisedValue": 0, "unexercisedValue": 384162}, {"maxAge": 1, "name": "Mr. David A. Walsey J.D., L.L.M.", "title": "Senior Vice President of Corporate Affairs", "fiscalYear": 2021, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.1, "open": 3.15, "dayLow": 3.08, "dayHigh": 3.21, "regularMarketPreviousClose": 3.1, "regularMarketOpen": 3.15, "regularMarketDayLow": 3.08, "regularMarketDayHigh": 3.21, "exDividendDate": 1700092800, "beta": 0.73, "trailingPE": 0.80357146, "forwardPE": -0.5536028, "volume": 2478, "regularMarketVolume": 2478, "averageVolume": 101774, "averageVolume10days": 12730, "averageDailyVolume10Day": 12730, "marketCap": 20988010, "fiftyTwoWeekLow": 2.73, "fiftyTwoWeekHigh": 7.87, "priceToSalesTrailing12Months": 0.31440827, "fiftyDayAverage": 3.1492, "twoHundredDayAverage": 4.0444, "currency": "USD", "enterpriseValue": -24230144, "profitMargins": 0.39181, "floatShares": 4932247, "sharesOutstanding": 6662860, "sharesShort": 16077, "sharesShortPriorMonth": 6644, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0023999999, "heldPercentInsiders": 0.0039, "heldPercentInstitutions": 0.4108, "shortRatio": 0.07, "shortPercentOfFloat": 0.0029, "bookValue": 7.659, "priceToBook": 0.41128087, "lastFiscalYearEnd": 1688083200, "nextFiscalYearEnd": 1719705600, "mostRecentQuarter": 1711843200, "netIncomeToCommon": 26155000, "trailingEps": 3.92, "forwardEps": -5.69, "pegRatio": -9.0, "lastSplitFactor": "1:6", "lastSplitDate": 1355875200, "enterpriseToRevenue": -0.363, "enterpriseToEbitda": -1.169, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "MEIP", "underlyingSymbol": "MEIP", "shortName": "MEI Pharma, Inc.", "longName": "MEI Pharma, Inc.", "firstTradeDateEpochUtc": 1071757800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "75f4e209-abec-388e-adff-b91ac3ee4681", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.15, "targetHighPrice": 6.0, "targetLowPrice": 6.0, "targetMeanPrice": 6.0, "targetMedianPrice": 6.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 56552000, "totalCashPerShare": 8.488, "ebitda": 20735000, "totalDebt": 11667000, "quickRatio": 5.881, "currentRatio": 6.174, "totalRevenue": 66754000, "debtToEquity": 22.863, "revenuePerShare": 10.019, "returnOnAssets": 0.12399, "returnOnEquity": 0.61265, "freeCashflow": 7191875, "operatingCashflow": -43776000, "grossMargins": 1.51925, "ebitdaMargins": 0.31062, "operatingMargins": 0.30528998, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]